Clinical risk factors for developing brain metastases during first-line (chemo-)immunotherapy in patients with non-small cell lung cancer without known baseline brain metastases
BM detection during first-line (chemo-)ICI is relatively low in patients with stage IV NSCLC without known baseline BM, but the burden (symptoms) is high. Upon validation, the identified risk factors may support selective brain imaging in high-risk patients, avoiding routine screening in low-risk patients.
Authors
- C. Steendam (ORCID: https://orcid.org/0000-0002-8487-9344)
- Lizza Hendriks (ORCID: https://orcid.org/0000-0002-3521-2535)
- Lucie B.M. Hijmering Kappelle
- Wouter Heero van Geffen (ORCID: https://orcid.org/0000-0002-5976-0974)
- Juliette Degens (ORCID: https://orcid.org/0000-0003-0279-9656)
- Michelle Steens
- Cordula Pitz
- Magdolen Youssef-El Soud
- Frederike Bensch (ORCID: https://orcid.org/0000-0001-8648-0612)
- Anna Sadowska (ORCID: https://orcid.org/0000-0002-8842-4312)
- Jarno W J Huijs (ORCID: https://orcid.org/0000-0001-9117-6885)
- Dirk K.M. De Ruysscher
- Tom M T de Schrevel
Institutions
- University Medical Center Groningen (NL)
- Radboud University Nijmegen (NL)
- Maastricht University Medical Centre (NL)
- Catharina Ziekenhuis (NL)
- Radboud University Medical Center (NL)
- Maastricht University (NL)
- VieCuri Medisch Centrum (NL)
- Máxima Medisch Centrum (NL)
- Zuyderland Medisch Centrum (NL)
- Laurentius Ziekenhuis (NL)
- Maastro Clinic (NL)
Publication Details
- Journal
- Lung Cancer
- Published
- 2025-09-02
- DOI
- https://doi.org/10.1016/j.lungcan.2025.108745
- Citations
- 1
- Primary Topic
- Brain Metastases and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- Pfizer